Search

Your search keyword '"Meningococcal Reference Laboratory [Madrid]"' showing total 3 results
Start Over Author "Meningococcal Reference Laboratory [Madrid]"
3 results on '"Meningococcal Reference Laboratory [Madrid]"'

1. Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development

Author

Brehony, Carina, Trotter, Caroline L., Ramsay, Mary E., Chandra, Manosree, Jolley, Keith A., van der Ende, Arie, Carion, Françoise, Berthelsen, Lene, Hoffmann, Steen, Harðardóttir, Hjördís, Vazquez, Julio A., Murphy, Karen, Toropainen, Maija, Caniça, Manuela, Ferreira, Eugenia, Diggle, Mathew, Edwards, Giles F., Taha, Muhamed-Kheir, Stefanelli, Paola, Kriz, Paula, Gray, Steve J., Fox, Andrew J., Jacobsson, Susanne, Claus, Heike, Vogel, Ulrich, Tzanakaki, Georgina, Heuberger, Sigrid, Caugant, Dominique A., Frosch, Matthias, Maiden, Martin C. J., Amsterdam institute for Infection and Immunity, Medical Microbiology and Infection Prevention, Department of Zoology [Oxford], University of Oxford [Oxford], University of Cambridge [UK] (CAM), Public Health England [London], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Institut Scientifique de Santé Publique [Belgique] - Scientific Institute of Public Health [Belgium] (WIV-ISP), Réseau International des Instituts Pasteur (RIIP), Statens Serum Institut [Copenhagen], Landspitali National University Hospital of Iceland, Meningococcal Reference Laboratory [Madrid], Irish Meningococcal and Meningitis Reference Laboratory, National Institute for Health and Welfare [Helsinki], National Reference Laboratory of Antibiotic Resistances and Healthcare Associated Infections (NRL-AMR-HAI), Department of Infectious Diseases, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), The Scottish Haemophilus, Legionella, Meningococcus, and Pneumococcus Reference Laboratory, Centre National de Référence des Méningocoques et Haemophilus influenzae - National Reference Center Meningococci and Haemophilus influenzae (CNR), Institut Pasteur [Paris], Department of Infectious, Parasitic and Immune-Mediated Diseases [Rome], Istituto Superiore di Sanita [Rome], National Institute of Public Health [Prague], Manchester Royal Infirmary, University of Manchester [Manchester], Örebro University Hospital [Örebro, Sweden], Institut für Hygiene und Mikrobiologie [Würzburg], National Meningitis Reference Laboratory, National School of Public Health Athens, Institute for Medical Microbiology and Hygiene [Graz], Norwegian Institute of Public Health [Oslo] (NIPH), This publication made use of the Neisseria Multi Locus Sequence Typing website (http://pubmlst.org/neisseria) developed by Keith Jolley and sited at the University of Oxford. The development of this site has been funded by the Wellcome Trust and the European Union., University of Oxford, Institut Pasteur [Paris] (IP), and Istituto Superiore di Sanità (ISS)

Subjects
Adult, MESH: Sequence Analysis, DNA, Adolescent, Meningococcal Vaccines, Meningitis, Meningococcal, Neisseria meningitidis, Neisseria meningitidis, Serogroup B, MESH: Base Sequence, MESH: Neisseria meningitidis, Young Adult, Age Distribution, MESH: Child, MESH: Neisseria meningitidis, Serogroup B, MESH: Bacterial Capsules, Humans, ddc:610, Child, MESH: Age Distribution, Bacterial Capsules, MESH: Adolescent, Vaccines, Antigens, Bacterial, MESH: Humans, Base Sequence, MESH: Child, Preschool, MESH: Meningitis, Meningococcal, Infant, MESH: Adult, Sequence Analysis, DNA, MESH: Infant, MESH: Multilocus Sequence Typing, MESH: Young Adult, Child, Preschool, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, MESH: Antigens, Bacterial, Multilocus Sequence Typing
Abstract

International audience; New vaccines targeting meningococci expressing serogroup B polysaccharide have been developed, with some being licensed in Europe. Coverage depends on the distribution of disease-associated genotypes, which may vary by age. It is well established that a small number of hyperinvasive lineages account for most disease, and these lineages are associated with particular antigens, including vaccine candidates. A collection of 4,048 representative meningococcal disease isolates from 18 European countries, collected over a 3-year period, were characterized by multilocus sequence typing (MLST). Age data were available for 3,147 isolates. The proportions of hyperinvasive lineages, identified as particular clonal complexes (ccs) by MLST, differed among age groups. Subjects 25-year-olds were more likely to experience disease due to less common ccs and unassigned STs. Younger and older subjects were vulnerable to a more diverse set of genotypes, indicating the more clonal nature of genotypes affecting adolescents and young adults. Knowledge of temporal and spatial diversity and the dynamics of meningococcal populations is essential for disease control by vaccines, as coverage is lineage specific. The nonrandom age distribution of hyperinvasive lineages has consequences for the design and implementation of vaccines, as different variants, or perhaps targets, may be required for different age groups.

Published
2014
Full Text
View/download PDF

2. The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease

Author

Marco Aurélio Palazzi Sáfadi, Johan Holst, Muhamed-Kheir Taha, Anne von Gottberg, Lee H. Harrison, Annelies Wilder-Smith, Stanley A. Plotkin, Ray Borrow, Julio A. Vázquez, Stephen I. Pelton, F. Marc LaForce, University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE), Boston University School of Medicine (BUSM), Boston University [Boston] (BU), National University of Singapore (NUS), Norwegian Institute of Public Health [Oslo] (NIPH), FCM Santa Casa de São Paulo School of Medical Sciences [São Paulo], Meningococcal Reference Laboratory [Madrid], Institute of Health Carlos III, PATH Europe [Ferney Voltaire], National Institute for Communicable Diseases [Johannesburg] (NICD), Manchester Royal Infirmary, University of Manchester [Manchester], University of Pennsylvania, Members of the GMI Chairman: Stanley Plotkin, MD (University of Pennsylvania, Doylestown, PA, USA). Steering Committee: Carl Frasch, PhD (Frasch Biologics Consulting, Martinsburg, WV, USA), Sunil Gupta, MBBS, MD (National Institute of Communicable Diseases, Delhi, India), Lee H. Harrison, MD (University of Pittsburgh, Pittsburgh, PA, USA), Ziad Memish, MD (Ministry of Health, Riyadh, Saudi Arabia), Andrew J. Pollard, FRCPCH, PhD (University of Oxford, Oxford, UK), Muhamed-Kheir Taha, MD, PhD (Institut Pasteur, Paris, France), Julio Vazquez, PhD (Institute of Health Carlos III, Madrid, Spain), Anne von Gottberg, MBBCh (National Institute for Communicable Diseases, Johannesburg, South Africa). Summit Members: Richard Adegbola, MSc, PhD (Bill and Melinda Gates Foundation, Seattle, WA, USA), Colin Block, MBBCh, PhD (Hadassah-Hebrew University Medical Centre, Jerusalem, Israel), Ray Borrow, PhD, FRCPath (Health Protection Agency, Manchester, UK), Tom Clark, MD, MPH (Centers for Disease Control and Prevention, Atlanta, GA, USA), Benoit Dervaux, PhD (Faculty of Medicine, University 'Droit et Santé', Lille, France), Johan Holst, PhD, MSc (Norwegian Institute of Public Health, Oslo, Norway), Sheldon Kaplan, MD (Baylor College of Medicine, Houston, TX, USA), Marc LaForce, MD (Meningitis Vaccine Project, Ferney, France), Xiaofeng Liang, MD (National Immunization Program, China CDC, Beijing, China), Diana Martin, PhD (Institute of Environmental Science and Research, Poriru, New Zealand), Stephen Pelton, MD (Boston University Schools of Medicine and Public Health, Boston, MA, USA), Marco Safadi, MD (FCM Da Santa Casa de São Paulo, São Paulo, Brazil), Samir Saha, PhD (Bangladesh Institute of Child Health, Dhaka, Bangladesh), Franklin Sotolongo, MD (Finlay Institute, Havana, Cuba), Irina Stanislavovna Koroleva, MD, PhD (Central Research Institute of Epidemiology, Moscow, Russia), Annelies Wilder-Smith, MD, PhD, MIH (National University of Singapore, Singapore)., and University of Pennsylvania [Philadelphia]

Subjects
medicine.medical_specialty, MESH: Vaccines, Conjugate, Meningococcal Vaccines, Meningococcal vaccine, Meningococcal disease, MESH: Immunization Programs, MESH: Meningococcal Infections, MESH: Meningococcal Vaccines, MESH: Population Surveillance, Epidemiology, medicine, Humans, Disease burden, Vaccines, Conjugate, MESH: Humans, General Veterinary, General Immunology and Microbiology, business.industry, Immunization Programs, Public health, Public Health, Environmental and Occupational Health, medicine.disease, Vaccination, Meningococcal Infections, Infectious Diseases, Immunization, Vaccination policy, Family medicine, Population Surveillance, Immunology, Molecular Medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Public Health, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, business, MESH: Public Health
Abstract

International audience; The Global Meningococcal Initiative (GMI) is composed of an international group of scientists, clinicians and public health officials with expertise in meningococcal immunology, epidemiology and prevention. The primary goal of the GMI is the promotion of the global prevention of invasive meningococcal disease through education and research. The GMI members reviewed global meningococcal disease epidemiology, immunization strategies, and research needs. Over the past decade, substantial advances in meningococcal vaccine development have occurred and much has been learned about prevention from countries that have incorporated meningococcal vaccines into their immunization programs. The burden of meningococcal disease is unknown for many parts of the world because of inadequate surveillance, which severely hampers evidence-based immunization policy. As the field of meningococcal vaccine development advances, global surveillance for meningococcal disease needs to be strengthened in many regions of the world. For countries with meningococcal vaccination policies, research on vaccine effectiveness and impact, including indirect effects, is crucial for informing policy decisions. Each country needs to tailor meningococcal vaccination policy according to individual country needs and knowledge of disease burden. Innovative approaches are needed to introduce and sustain meningococcal vaccination programs in resource-poor settings with a high incidence of meningococcal disease.

Published
2011
Full Text
View/download PDF

3. Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development.

Author

Brehony C, Trotter CL, Ramsay ME, Chandra M, Jolley KA, van der Ende A, Carion F, Berthelsen L, Hoffmann S, Harðardóttir H, Vazquez JA, Murphy K, Toropainen M, Caniça M, Ferreira E, Diggle M, Edwards GF, Taha MK, Stefanelli P, Kriz P, Gray SJ, Fox AJ, Jacobsson S, Claus H, Vogel U, Tzanakaki G, Heuberger S, Caugant DA, Frosch M, and Maiden MC

Subjects
Adolescent, Adult, Age Distribution, Antigens, Bacterial immunology, Base Sequence, Child, Child, Preschool, Humans, Infant, Meningitis, Meningococcal immunology, Meningitis, Meningococcal microbiology, Multilocus Sequence Typing, Neisseria meningitidis isolation & purification, Sequence Analysis, DNA, Young Adult, Bacterial Capsules immunology, Meningitis, Meningococcal prevention & control, Meningococcal Vaccines immunology, Neisseria meningitidis immunology, Neisseria meningitidis, Serogroup B immunology
Abstract

New vaccines targeting meningococci expressing serogroup B polysaccharide have been developed, with some being licensed in Europe. Coverage depends on the distribution of disease-associated genotypes, which may vary by age. It is well established that a small number of hyperinvasive lineages account for most disease, and these lineages are associated with particular antigens, including vaccine candidates. A collection of 4,048 representative meningococcal disease isolates from 18 European countries, collected over a 3-year period, were characterized by multilocus sequence typing (MLST). Age data were available for 3,147 isolates. The proportions of hyperinvasive lineages, identified as particular clonal complexes (ccs) by MLST, differed among age groups. Subjects <1 year of age experienced lower risk of sequence type 11 (ST-11) cc, ST-32 cc, and ST-269 cc disease and higher risk of disease due to unassigned STs, 1- to 4-year-olds experienced lower risk of ST-11 cc and ST-32 cc disease, 5- to 14-year-olds were less likely to experience ST-11 cc and ST-269 cc disease, and ≥25-year-olds were more likely to experience disease due to less common ccs and unassigned STs. Younger and older subjects were vulnerable to a more diverse set of genotypes, indicating the more clonal nature of genotypes affecting adolescents and young adults. Knowledge of temporal and spatial diversity and the dynamics of meningococcal populations is essential for disease control by vaccines, as coverage is lineage specific. The nonrandom age distribution of hyperinvasive lineages has consequences for the design and implementation of vaccines, as different variants, or perhaps targets, may be required for different age groups., (Copyright © 2014 Brehony et al.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results